吉林大学学报(医学版) ›› 2024, Vol. 50 ›› Issue (3): 854-863.doi: 10.13481/j.1671-587X.20240333
• 综述 • 上一篇
收稿日期:
2023-02-03
出版日期:
2024-05-28
发布日期:
2024-07-01
通讯作者:
尹霞
E-mail:jdyyyx@jlu.edu.cn
作者简介:
张 莉(1995-),女,山东省临沂市人,在读硕士研究生,主要从事高血压和冠心病诊治方面的研究。
基金资助:
Li ZHANG,Binfeng XIA,Huihui HUANG,Ru WANG,Min KONG,Xia YIN()
Received:
2023-02-03
Online:
2024-05-28
Published:
2024-07-01
Contact:
Xia YIN
E-mail:jdyyyx@jlu.edu.cn
摘要:
肿瘤治疗相关心血管毒性(CTR-CVT)逐渐成为影响肿瘤幸存者预后的关键因素。以血管内皮生长因子(VEGF)为靶点研发的VEGF及其受体抑制剂(VEGFIs)作为新型抗肿瘤药物现已广泛应用于临床,可延长肿瘤患者的生存周期,改善患者预后,但VEGFIs诱导的高血压作为其最常见的CTR-CVT,可能会限制和影响其应用并引起严重心血管疾病(CVD)。对应用VEGFIs治疗的肿瘤患者应密切监测血压,早期评估,优化管理,使患者获得最佳的抗肿瘤疗效和最低的CTR-CVT风险。现就VEGFIs相关性高血压的临床表现、发病机制、诊断和治疗策略进行综述,旨在为临床医生更好地管理和应对VEGFIs相关性高血压提供参考。
中图分类号:
张莉,夏彬凤,黄慧慧,王茹,孔敏,尹霞. 血管内皮生长因子及其受体抑制剂相关性高血压病理生理机制及临床诊疗的研究进展[J]. 吉林大学学报(医学版), 2024, 50(3): 854-863.
Li ZHANG,Binfeng XIA,Huihui HUANG,Ru WANG,Min KONG,Xia YIN. Research progress in pathophysiological mechanism and clinical diagnosis and treatment of hypertension associated with vascular endothelial growth factor and its receptor inhibitors[J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 854-863.
1 | LYON A R, LÓPEZ-FERNÁNDEZ T, COUCH L S, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J]. Eur Heart J, 2022, 43(41): 4229-4361. |
2 | TOTZECK M, SCHULER M, STUSCHKE M, et al. Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease[J]. Int J Cardiol, 2019, 280: 163-175. |
3 | WILLIAMS B, MANCIA G, SPIERING W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39(33): 3021-3104. |
4 | QUINTANILHA J C F, WANG J, SIBLEY A B, et al. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients[J]. Br J Cancer, 2022, 126(2): 265-274. |
5 | LI M G, MULKEY F, JIANG C, et al. Identification of a genomic region between SLC29A1 and HSP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (alliance)[J]. Clin Cancer Res, 2018, 24(19): 4734-4744. |
6 | 杨晓蕾, 管 博, 吕海辰, 等. 抗癌药物血管内皮生长因子抑制剂相关高血压的管理策略[J]. 中华心血管病杂志, 2021, 49(10): 957-962. |
7 | CALETTI S, PAINI A, COSCHIGNANO M A, et al. Management of VEGF-targeted therapy-induced hypertension[J]. Curr Hypertens Rep, 2018, 20(8): 68. |
8 | VERSMISSEN J, MIRABITO COLAFELLA K M, KOOLEN S L W, et al. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension[J]. Cardiovasc Res, 2019, 115(5): 904-914. |
9 | CIGNARELLA A, FADINI G P, BOLEGO C, et al. Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges[J]. Cardiovasc Res, 2022, 118(4): 988-1003. |
10 | RAMJIAWAN R R, GRIFFIOEN A W, DUDA D G. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?[J]. Angiogenesis, 2017, 20(2): 185-204. |
11 | IVANYI P, BEUTEL G, DREWES N, et al. Therapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinib[J]. Clin Genitourin Cancer, 2017, 15(2): 280-290.e3. |
12 | ROVIELLO G, PACIFICO C, CORONA P, et al. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis[J]. Invest New Drugs, 2017, 35(4): 518-523. |
13 | QI W X, SHEN Z, TANG L N, et al. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis[J]. Clin Drug Investig, 2014, 34(4): 231-240. |
14 | QI W X, HE A N, SHEN Z, et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2013, 76(3): 348-357. |
15 | BÆK MØLLER N, BUDOLFSEN C, GRIMM D, et al. Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment[J]. Int J Mol Sci, 2019, 20(19): 4712. |
16 | WU H X, DING X Y, ZHANG Y C, et al. Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: an updated systematic review and meta-analysis[J]. J Clin Hypertens, 2022, 24(6): 667-676. |
17 | CHEN J X, WANG J H. Risk of regorafenib-induced cardiovascular events in patients with solid tumors: a systematic review and meta-analysis[J]. Medicine, 2018, 97(41): e12705. |
18 | WANG Z X, XU J, NIE W W, et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2014, 70(2): 225-231. |
19 | MILLING R V, GRIMM D, KRÜGER M, et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension[J]. Int J Mol Sci, 2018, 19(10): 3258. |
20 | PINKHAS D, HO T, SMITH S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development[J]. Cardiooncology, 2017, 3: 5. |
21 | YANG X W, PAN X, CHENG X S, et al. Risk of hypertension with sorafenib use in patients with cancer: a meta-analysis from 20, 494 patients[J]. Am J Ther, 2017, 24(1): e81-e101. |
22 | MOTZER R, ALEKSEEV B, RHA S Y, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. |
23 | QI W X, SHEN Z, LIN F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials[J]. Br J Clin Pharmacol, 2013, 75(4): 919-930. |
24 | CHOUEIRI T K, HESSEL C, HALABI S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update[J]. Eur J Cancer, 2018, 94: 115-125. |
25 | HONG S, DANIELS B, VAN LEEUWEN M T, et al. Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors[J]. Discov Oncol, 2022, 13(1): 6. |
26 | VAN DORST D C H, KABADAYI S, OOMEN-DE HOOP E, et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study[J]. J Am Heart Assoc, 2023, 12(1): e028050. |
27 | COLLINS T, GRAY K, BISTA M, et al. Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension[J]. Br J Pharmacol, 2018, 175(4): 618-630. |
28 | QUINTANILHA J C F, LIU Y M, ETHERIDGE A S, et al. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)[J]. Angiogenesis, 2022, 25(1): 47-55. |
29 | CORTI F, SIMONS M. Modulation of VEGF receptor 2 signaling by protein phosphatases[J]. Pharmacol Res, 2017, 115: 107-123. |
30 | 赵小建, 王 琛, 刘 敏, 等. 抗血管生成靶向药物导致高血压的研究进展[J]. 临床荟萃, 2020, 35(8): 749-754. |
31 | MUKAI M, KOMORI K, OKA T. Mechanism and management of cancer chemotherapy-induced atherosclerosis[J]. J Atheroscler Thromb, 2018, 25(10): 994-1002. |
32 | LANKHORST S, BAELDE H J, KAPPERS M H, et al. Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib[J]. Hypertension, 2015, 66(3): 543-549. |
33 | MÄKI-PETÄJÄ K M, MCGEOCH A, YANG L L, et al. Mechanisms underlying vascular endothelial growth factor receptor inhibition-induced hypertension: the HYPAZ trial[J]. Hypertension, 2021, 77(5): 1591-1599. |
34 | NEVES K B, RIOS F J, VAN DER MEY L, et al. VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes[J]. Hypertension, 2018, 71(4): 638-647. |
35 | VAN DEN MEIRACKER A H, DANSER A H. Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition[J]. Hypertension, 2016, 68(1): 17-23. |
36 | 蒋 慧, 丁国华. VEGF 对肾脏调节作用的研究进展[J]. 医学研究杂志, 2017, 46(11): 182-185. |
37 | IZZEDINE H, ESCUDIER B, LHOMME C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center[J]. Medicine, 2014, 93(24): 333-339. |
38 | ESTRADA C C, MALDONADO A, MALLIPATTU S K. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities[J]. J Am Soc Nephrol, 2019, 30(2): 187-200. |
39 | BELCIK J T, QI Y, KAUFMANN B A, et al. Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer[J]. J Am Coll Cardiol, 2012, 60(7): 618-625. |
40 | THIJS A, VAN HERPEN C, VAN DER GRAAF W T A, et al. Early rise in aldosteron is correlated with increase in blood pressure in sunitinib treated patients with metastatic renal cell carcinoma[J]. Clin Ther, 2014, 36(8): e11. |
41 | GENNARI-MOSER C, KHANKIN E V, ESCHER G, et al. Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia[J]. Hypertension, 2013, 61(5): 1111-1117. |
42 | KAPPERS M H, VAN ESCH J H, SLUITER W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels[J]. Hypertension, 2010, 56(4): 675-681. |
43 | PANDEY A K, SINGHI E K, ARROYO J P, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease[J]. Hypertension, 2018, 71(2): e1-e8. |
44 | LANKHORST S, SEVERS D, MARKÓ L, et al. Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation?[J]. Hypertension, 2017, 69(5): 919-926. |
45 | TOUYZ R M, LANG N N, HERRMANN J, et al. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition[J]. Hypertension, 2017, 70(2): 220-226. |
46 | LOMBARDI P, ROSSINI D, CRESPI V, et al. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: an individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature[J]. Cancer Treat Rev, 2022, 103: 102326. |
47 | OSUMI H, SHINOZAKI E, OOKI A, et al. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy[J]. Cancer Med, 2021, 10(2): 615-625. |
48 | DUCO M R, MURDOCK J L, REEVES D J. Vascular endothelial growth factor inhibitor induced hypertension: retrospective analysis of the impact of blood pressure elevations on outcomes[J]. J Oncol Pharm Pract, 2022, 28(2): 265-273. |
49 | DUFFAUD F, SLEIJFER S, LITIÈRE S, et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials[J]. Eur J Cancer, 2015, 51(17): 2615-2623. |
50 | HURWITZ H I, DOUGLAS P S, MIDDLETON J P, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase Ⅲ studies[J]. Oncologist, 2013, 18(3): 273-280. |
51 | 熊宇麒, 李学军. 心血管疾病与恶性肿瘤的共同危险因素及药物的影响[J]. 药学学报, 2020, 55(1): 1-7. |
52 | MEHTA L S, WATSON K E, BARAC A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American heart association[J]. Circulation, 2018, 137(8): e30-e66. |
53 | CURIGLIANO G, LENIHAN D, FRADLEY M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations[J]. Ann Oncol, 2020, 31(2): 171-190. |
54 | MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. |
55 | VAN DORST D C H, DOBBIN S J H, NEVES K B, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients[J]. Circ Res, 2021, 128(7): 1040-1061. |
56 | PINTER M, KWANTEN W J, JAIN R K. Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events[J]. Clin Cancer Res, 2018, 24(16): 3803-3812. |
57 | WALIANY S, SAINANI K L, PARK L S, et al. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor[J]. JACC CardioOncol, 2019, 1(1): 24-36. |
58 | ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801. |
59 | DE MACEDO ANDRADE A C, FELIX F A, FRANÇA G M, et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2022, 78(6): 919-930. |
60 | COHEN J B, BROWN N J, BROWN S A, et al. Cancer therapy-related hypertension: a scientific statement from the American heart association[J]. Hypertension, 2023, 80(3): e46-e57. |
[1] | 李贯绯,张逊娟,庞猛,李淞. 慢性直立不耐受人群血流动力学模式与缺血性卒中发病风险关系的前瞻性研究[J]. 吉林大学学报(医学版), 2024, 50(2): 473-480. |
[2] | 余淑华,刘朏,吴倩倩,杨东伟. 藏红花素对自发性高血压大鼠血管内皮功能障碍及动脉粥样硬化的作用及其ROCK/JNK信号通路机制[J]. 吉林大学学报(医学版), 2022, 48(6): 1481-1489. |
[3] | 陈月,于蕾,兰晓馨,贾思琪,袁海波. 氧降和复氧速率对阻塞性睡眠呼吸暂停患者昼夜血压的影响[J]. 吉林大学学报(医学版), 2021, 47(4): 1008-1013. |
[4] | 王芃, 李挪, 黄山, 李铁男, 郎晓峰, 刘伟. 幕上高血压脑出血患者不同手术方式的临床疗效比较[J]. 吉林大学学报(医学版), 2019, 45(03): 667-672. |
[5] | 钱楚岳, 宋君莉, 刘乃萌, 孙珉丹. 利福平对高血压患者降压药物效果的影响1例报告及文献复习[J]. 吉林大学学报(医学版), 2019, 45(02): 418-421. |
[6] | 谢文杰, 龙海权, 宋代富, 区德锦, 江岚, 陈晞明, 黄炯华. 高血压左心室肥厚患者血浆中自噬相关蛋白9a的水平及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(04): 786-790. |
[7] | 金润浩, 徐忠福, 李庆, 全贞玉, 韩春姬. 血压身高比在吉林省延吉市青少年高血压筛查中的应用[J]. 吉林大学学报(医学版), 2018, 44(03): 639-645. |
[8] | 蓝永洪, 饶朗毓, 杨智, 黄明媚, 牛海艳, 齐亚灵. 妊娠高血压综合征患者胎盘组织中HIF-1α和HSP70的表达及其意义[J]. 吉林大学学报(医学版), 2018, 44(02): 346-349. |
[9] | 郝铮, 刘楠, 王路, 李东原, 赵丛海, 刘伟明, 陈卓, 张金男. 立体定向与简易定位颅内置管治疗中等量高血压脑出血患者临床效果比较[J]. 吉林大学学报(医学版), 2017, 43(01): 130-134. |
[10] | 周叶, 程云章, 黄敬垣. 高血压伴冠状动脉狭窄患者左心房功能实时三平面应变率成像特征及其意义[J]. 吉林大学学报(医学版), 2016, 42(05): 1019-1023. |
[11] | 赵桐荫, 褚运松, 赵惠子, 刘志明, 曹宁, 李忠民. 吉林省农村地区居民膳食模式与高血压关系的调查分析[J]. 吉林大学学报(医学版), 2016, 42(02): 400-404. |
[12] | 徐丽斯, 何金婷, 莽靖, 王学菊, 王丽萍, 那万里, 邵延坤, 徐忠信. 以头痛为首发症状的嗜铬细胞瘤1例报告并文献复习[J]. 吉林大学学报(医学版), 2015, 41(05): 1027-1031. |
[13] | 陈国志, 张镜宇, 刘飞. 有氧运动对肥胖性高血压大鼠肾素-血管紧张素系统和心功能的改善作用[J]. 吉林大学学报(医学版), 2015, 41(03): 563-567. |
[14] | 蒋玲玲, 杨雪玲, 吕薇, 张越, 殷雨天, 王钰涵, 王瑞, 张鹏, 李波, 姚燕. HLA-DRB1基因多态性与原发性高血压发病的关联性分析[J]. 吉林大学学报(医学版), 2015, 41(03): 619-624. |
[15] | 杨四宝, 刘雪岩, 李冰, 丁梅, 贺玉泉, 杨萍. 吉林汉族人群ERAP1基因3'UTR单核苷酸多态性与原发性高血压的关联性分析[J]. 吉林大学学报(医学版), 2015, 41(02): 383-388. |
|